8-K: Current report
10-Q/A: Quarterly report (Amendment)
8-K: SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61%
10-Q: Q2 2024 Earnings Report
NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
8-K: Current report
DEF 14C: Definitive information statements
8-K: Current report
PRE 14C: Preliminary information statement not related to a contested matter or merger/acquisition
8-K: Current report
8-K: Current report
8-K: Current report
8-K: SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER RESULTS: REVENUES UP 54%
10-Q: Q1 2024 Earnings Report
NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
8-K: Current report
8-K: Current report
8-K: Current report
Sunshine Biopharma | 8-K: Current report
Sunshine Biopharma | 10-K: FY2023 Annual Report
No Data
No Data